Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ficlatuzumab + erlotinib
- Development stage
- Unknown
- Lead developer
- AVEO Oncology
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous, Oral
01
Overview
AV-299 (ficlatuzumab) is a potent anti-hepatocyte growth factor (HGF) monoclonal antibody developed by AVEO Pharmaceuticals. It targets and neutralizes HGF to inhibit the HGF/c-Met signaling pathway implicated in tumor growth and metastasis. Erlotinib is an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor marketed as Tarceva. The combination of ficlatuzumab (AV-299) with erlotinib has been investigated for enhanced anti-tumor activity in cancers characterized by aberrant HGF/c-Met and EGFR signaling, particularly non-small cell lung cancer (NSCLC). Preclinical studies demonstrated additive effects when both drugs were used together. Clinical trials have evaluated this combination for safety and efficacy in patients with solid tumors including NSCLC[3][4].
- Brand names
- Tarceva
- Other names
- AV-299AV299AV 299SCH 900105SCH900105SCH-900105ficlatuzumab
02
Targets
HGF (Hepatocyte growth factor)EGFR (Epidermal growth factor receptor)
Beyond the preview
Go deeper on ficlatuzumab + erlotinib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ficlatuzumab + erlotinib.